The global 3D bioprinting market size is expected to reach USD 5.3 billion by 2030, expanding at a CAGR of 15.8% during the forecast period, according to a new report by Grand View Research, Inc. Rising cases of COVID-19 and increasing prevalence of chronic diseases are some of the major factors contributing towards industry growth. During the COVID-19 pandemic, 3D printing has stepped up to become a vital technology to support improved healthcare and our general response to this emergency.
The COVID-19 pandemic is ever increasing since it was first identified in China in December 2019. Until January 12, 2021, more than 91.5 million cases of COVID-19 were reported globally, with more than 1,956,880 deaths, across the globe. This pandemic has fast-tracked the development of vaccines and drug testing. There are currently more than 50 COVID-19 vaccine candidates in trials.
In the meantime, various 3D bioprinting companies are focusing on the research and development of artificial tissues. With the help of U-FAB and other bioprinting technologies, the CLECELL company has created respiratory epithelium artificial tissue which will help to prevent infection and tissue injury through the use of the mucociliary elevator. This pandemic has not only affected the well-being of people, but has also affected the economy, and various other healthcare infrastructures worldwide. This has severely disrupted the medical devices and pharmaceutical supply chains across the world. In such a critical situation, various 3D bioprinting companies have created a global movement to supply emergency medical equipment such as ventilators, and personal protection equipment (PPE), to the healthcare workers.
North America held the highest share of the market, accounting for about 31.6% of the market share in 2021. Increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region. Whereas, Asia Pacific is anticipated to witness increased technological development in the pharmaceutical and biopharmaceutical sectors.
Request a free sample copy or view report summary: 3D Bioprinting Market Report
The medical segment accounted for the largest share of 36.8% in 2021 due to the increasing investment made in R&D
The magnetic levitation segment is anticipated to witness the highest CAGR of 14.2% during the forecast period due to technological development, and increasing adoption of magnetic levitation techniques by various innovators
North America dominated the market in 2021 with a share of 31.6%. Growing government expenditure on the healthcare industry is one of the major factors driving the market in this region
Grand View Research has segmented the global 3D bioprinting market on the basis of technology, application, and region:
3D Bioprinting Technology Outlook (Revenue, USD Million, 2017 - 2030)
3D Bioprinting Application Outlook (Revenue, USD Million, 2017 - 2030)
Tissue and organ generation
Prosthetics and implants
Consumer/Personal Product Testing
Food and Animal Product
3D Bioprinting Regional Outlook (Revenue, USD Million, 2017 - 2030)
Middle East & Africa
List of Key Players in the 3D Bioprinting Market
Organovo Holdings, Inc.
Inventia Life Science PTY LTD
Vivax Bio, LLC
Cyfuse Biomedical K.K.
3D Bioprinting Solutions
Regemat 3D S.L.
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."